Tvaster Genkalp

Tvaster Genkalp is a molecular diagnostic company specializing in liquid biopsy services for cancer and other diseases, utilizing droplet digital PCR (ddPCR) technology. The company focuses on providing affordable molecular diagnostic solutions that identify genetic and epigenetic modifications, aiding oncologists in making informed decisions. Tvaster Genkalp's flagship product, Episcreen Liver, is designed for hepatocellular carcinoma (HCC) screening, surveillance, and treatment response monitoring. The platform boasts an 89% sensitivity rate, significantly higher than traditional AFP testing, which stands at 60%. The company leverages hypermethylation signals to detect active tumors, offering a more reliable alternative to AFP, which often remains negative for a substantial portion of HCC patients. Tvaster Genkalp aims to bridge the gap between clinicians and scientists by delivering accessible healthcare solutions. The integration of machine learning with their methylation profiling platform allows for precise cancer staging, as demonstrated by the well-defined clustering of cancer stages in clinical studies. Keywords: liquid biopsy, HCC screening, ddPCR, methylation profiling, cancer diagnostics, affordable healthcare, genetic modifications, epigenetic modifications, machine learning, oncologists.